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A B S T R A C T
Objectives: The clinical benefit of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus
twice-daily budesonide/formoterol (BUD/FOR) for patients with symptomatic chronic obstructive pulmonary
disease (COPD) was demonstrated in a clinical trial setting (FULFIL [NCT02345161]). The lifetime cost-effec-
tiveness analysis of FF/UMEC/VI versus BUD/FOR, based on FULFIL data, is reported here.
Methods: A previously developed and validated GALAXY-COPD linked-risk equation model was used to assess
the cost-effectiveness of FF/UMEC/VI from the UK National Health Service (NHS) perspective. Baseline char-
acteristics and efficacy results from FULFIL and UK NHS reference cost data (2017) were included as inputs.
Exacerbation rates (undiscounted), costs, life years (LYs; undiscounted) and quality-adjusted life years (QALYs),
and the incremental cost-effectiveness ratio (ICER) were calculated over a lifetime horizon. Costs and QALYs
were discounted at 3.5% per year, beyond one year, in accordance with National Institute for Health and Care
Excellence (NICE) guidelines. Deterministic and probabilistic sensitivity analyses were performed to evaluate the
robustness of the results.
Results: Predicted cumulative exacerbations per patient over a lifetime were 8.393 with FF/UMEC/VI and
10.456 with BUD/FOR. Patients receiving FF/UMEC/VI gained an additional 0.764 LYs and 0.492 QALYs, at an
additional mean cost of £1,652, resulting in an ICER of £3,357 per QALY gained (95% confidence interval:
£1,816, £5,194) compared with BUD/FOR. The ICER remained below £6,000 in all but one of the scenario and
sensitivity analyses.
Conclusions: Compared with BUD/FOR, treatment with FF/UMEC/VI was predicted to improve health outcomes
at an additional cost that suggests it would be cost-effective for patients with COPD in the UK.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by
persistent symptoms and airflow limitation and is one of the most
common causes of preventable death worldwide [1–3]. COPD also
imposes a high economic burden on healthcare systems due to physi-
cian visits, emergency room (ER) visits and hospitalizations [2,4]. In
the United Kingdom (UK), the cost of COPD in 2011 was estimated to be
£1.9 billion [5]. Based on patterns of COPD prevalence, these costs are
likely to increase in future years. In addition to medical costs, the
chronic and debilitating nature of COPD, particularly dyspnea and
physical activity limitation, significantly reduces patients’ health-re-
lated quality of life (HRQoL) [6–9].
The aim of pharmacological therapy in COPD is to reduce symp-
toms, reduce the risk and severity of exacerbations and improve HRQoL
[3]. Escalating patients’ therapy may be required to achieve treatment
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goals. In patients with moderate-to-severe COPD, inhaled combination
therapy of drugs with differing mechanisms of action has been shown to
give better symptom reduction and a lower risk of exacerbations com-
pared with monotherapy [3]. According to the most recent Global In-
itiative for Chronic Obstructive Lung Disease (GOLD) strategy docu-
ment, an inhaled corticosteroid/long-acting muscarinic antagonist/
long-acting β2-agonist (ICS/LAMA/LABA) combination is re-
commended in patients with significant symptoms, despite combination
therapy with ICS/LABA or LAMA/LABA, and who are at risk of frequent
or severe exacerbations [3].
A triple therapy consisting of fluticasone furoate/umeclidinium/
vilanterol (FF/UMEC/VI) 100 μg/62.5 μg/25 μg formulated as a single
inhaler is indicated in the European Union for patients who are not
adequately treated with combination ICS/LABA therapy [10]. Single-
inhaler triple therapy (SITT) delivered as a once-daily dose may offer
advantages in convenience, patient preference, and more consistent
dosing, including in patients with multiple comorbidities, when com-
pared with the three medications given in multiple inhalers [11–14].
FULFIL (lung FUnction and quality of LiFe assessment in COPD with
closed trIpLe therapy; NCT02345161, GlaxoSmithKline plc. study
CTT116853), a phase III, randomized, double-blind clinical trial, sup-
ported the registration of FF/UMEC/VI and compared the once-daily
SITT (FF/UMEC/VI 100 μg/62.5 μg/25 μg delivered using the ELLIPTA
inhaler) with twice-daily single-inhaler ICS/LABA therapy (budeso-
nide/formoterol [BUD/FOR] 400 μg/12 μg, delivered using the
Turbuhaler) in patients with COPD [11]. In this study, once-daily
single-inhaler FF/UMEC/VI resulted in a statistically significant im-
provement in HRQoL and lung function (co-primary endpoints), com-
pared with twice-daily single-inhaler BUD/FOR after 24 weeks of
treatment. FF/UMEC/VI also resulted in a statistically significant re-
duction in the risk of exacerbations versus BUD/FOR. In a sub-popu-
lation who were studied for 52 weeks, FF/UMEC/VI resulted in a
statistically significant improvement in lung function and a statistically
significant reduction in exacerbation risk, plus a numerical improve-
ment in HRQoL, compared with BUD/FOR.
The current study was performed to compare the cost-effectiveness
of once-daily FF/UMEC/VI with that of twice-daily BUD/FOR, from a
UK National Health Service (NHS) perspective. The UK NHS now rou-
tinely requires evidence of cost-effectiveness, as well as clinical benefit,
before adopting new technologies. This analysis used a validated COPD
disease-progression model [15,16] and applied efficacy and treatment
persistence data from FULFIL.
2. Methods
2.1. Cost-effectiveness model
Cost-effectiveness, based on the FULFIL data, was analyzed using
the GALAXY-COPD disease progression model [15,16]. GALAXY-COPD
uses a linked-risk equation approach to forecast disease natural history,
including progression, associated healthcare costs (such as pharmacy
costs and cost of ER visits, hospitalization and outpatient visits), and
impact on quality-adjusted life years (QALYs) and survival. Statistical
risk equations to predict COPD natural history over time were derived
from the Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE) study [17]. Exacerbations, lung func-
tion (forced expiratory volume in 1 s [FEV1]), symptoms (dyspnea,
cough/sputum) and exercise capacity (based on the 6-minute walk test
[6MWT]), at baseline and at the previous model cycle, were considered
as independent variables. Statistical risk equations predicting health-
care resource utilization (HRU) were derived from the TOwards a Re-
volution in COPD Health (TORCH) study [18]. Full details of the GA-
LAXY-COPD model and its validation have been published previously
[15,16,19–21].
Abbreviations
6MWT 6-minute walk test
BMI Body mass index
BUD Budesonide
CAT COPD Assessment Test
CEAC Cost-effectiveness acceptability curve
CI Confidence interval
COPD Chronic obstructive pulmonary disease
CVD Cardiovascular disease
DRG Diagnosis related group
ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints
EQ-5D EuroQol-5D
ER Emergency room
EXACT-PRO EXAcerbations of Chronic pulmonary disease Tool
Patient-Reported Outcome
EXT Extension
FEV1 Forced expiratory volume in 1 s
FF Fluticasone furoate
FP Fluticasone propionate
FULFIL Lung FUnction and quality of LiFe assessment in COPD
with closed trIpLe therapy
FOR Formoterol
GLY Glycopyrronium
GOLD Global Initiative for Chronic Obstructive Lung Disease
HRQoL Health-related quality of life
HRU Healthcare resource utilization
ICER Incremental cost-effectiveness ratio
ICS Inhaled corticosteroid
ICU Intensive care unit
IMPACT InforMing the PAthway of COPD Treatment
IND Indacaterol
ITT Intent to treat
LABA Long-acting β2-agonist
LAMA Long-acting muscarinic antagonist
LY Life year
mMRC modified Medical Research Council
NHS National Health Service
NICE National Institute for Health and Care Excellence
ONS Office for National Statistics
PPPY Per patient per year
PSA Probabilistic sensitivity analysis
PSSRU Personal Social Services Research Unit
QALY Quality-adjusted life year
RR Relative risk
SAL Salmeterol
SALB Salbutamol
SGRQ St. George's Respiratory Questionnaire
SD Standard deviation
SE Standard error
SITT Single-inhaler triple therapy
SLS Salford Lung Study
SRC Scheduled reference costs
TIO Tiotropium
TORCH TOwards a Revolution in COPD Health
UK United Kingdom
UPLIFT Understanding Potential Long-term Impacts on Function
with Tiotropium
UMEC Umeclidinium
VI Vilanterol
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A UK NHS perspective was adopted for the analysis in the base case,
with costs inflated to 2017. A lifetime horizon was used in the study
base case, due to the chronic nature of COPD and based on guidance
from the National Institute for Health and Care Excellence (NICE) [22].
Time horizons of five and 10 years were explored in scenario analyses.
A 3.5% annual discount rate was applied for costs and benefits beyond
one year, in accordance with NICE guidelines [22]. Life years (LYs)
were kept undiscounted as a measure of predicted survival.
2.2. Model inputs
2.2.1. Population
Full details of patient inclusion criteria and other methods from the
FULFIL trial have been previously published [11]. Briefly, patients
(N= 1,810) were aged ≥40 years and suffered from advanced symp-
tomatic COPD (FEV1< 50% predicted and COPD Assessment Test
[CAT] score ≥10; or FEV1 ≥50–< 80% predicted, CAT ≥10 and ei-
ther ≥2 moderate exacerbations or ≥1 severe exacerbation in the
previous 12 months) [11]. The inclusion criteria allowed the enroll-
ment of patients with comorbidities, who make up a substantial
proportion of the COPD population but who are often excluded from
other trials. Patients were required to have been on maintenance COPD
medication for ≥3 months prior to screening and could continue their
pre-study maintenance therapy up to the time of randomization to
mimic switch scenarios in clinical practice. The intent-to-treat (ITT)
population included all randomized patients who received treatment,
regardless of treatment duration. A subgroup of patients who were
enrolled earliest were followed for a total of 52 weeks of treatment;
these patients comprised the extension (EXT) population (n=430).
To ensure a uniform baseline population for the analysis, the
baseline characteristics of the two treatment arms from FULFIL were
pooled. In FULFIL, baseline characteristics were similar between
treatment cohorts, including history of moderate/severe exacerbations
in the previous 12 months. For FF/UMEC/VI compared with BUD/FOR,
proportion of patients with: 0 exacerbations: 34% versus 35%, respec-
tively; 1 exacerbation: 28% in each arm; ≥2 exacerbations: 38% versus
37%, respectively [11]. Thus, the proportion of frequent and infrequent
exacerbators was virtually identical between the treatment arms. Ad-
ditionally, total scores in the St. George's Respiratory Questionnaire
(SGRQ) were similar between the arms: 53.0 (FF/UMEC/VI) versus
Table 1
Input characteristics (from FULFIL trial ITT population [11]).
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50.8 (BUD/FOR). Pooling the baseline characteristics therefore accu-
rately reflected the ITT population while avoiding noise in the analysis
and any potential bias in the comparison of FF/UMEC/VI and BUD/
FOR, although any such bias was unlikely to arise given the similarity of
the treatment arms. Because the GALAXY-COPD model requires base-
line values for dyspnea, fibrinogen and 6MWT scores, which were not
measured in FULFIL, they were estimated as follows: (i) The proportion
of patients with a baseline modified Medical Research Council (mMRC)
dyspnea score ≥2 (not measured) was assumed to be the same as the
proportion in FULFIL at baseline responding with ‘2’ (breathless during
light activity) or ‘3’ (breathless when washing or dressing) to question
eight of the EXAcerbations of Chronic pulmonary disease Tool Patient-
Reported Outcome (EXACT-PRO, captured in FULFIL) questionnaire,
‘Describe how breathless you were today’; (ii) baseline 6MWT scores
were predicted using the model risk equation; and (iii) fibrinogen
scores were predicted using an additional risk equation previously de-
veloped using ECLIPSE baseline data [17].
Table 1 shows the observed and estimated input parameter values
for the analysis, based on the characteristics of the FULFIL 24-week ITT
patient population; the same input parameter values were used for both
comparator arms in the study. Characteristics of the EXT population (52
weeks) are shown in Supplementary Table 1 and were used to inform
the model to conduct a subgroup analysis of the EXT population.
2.2.2. Treatment effect
The treatment effects, from FULFIL, used in the analysis were:
change from baseline in post-bronchodilator FEV1, change from base-
line in SGRQ total score, and reduction in moderate and severe ex-
acerbations. These have been published [11] or, in the case of exacer-
bations, relative risks for FF/UMEC/VI versus BUD/FOR were
calculated separately for moderate and severe exacerbations in an un-
published post-hoc analysis of FULFIL data. These inputs modified the
predicted outcomes of the first (annual) cycle of the model. After this,
evolution of FEV1 and exacerbation frequency, together with COPD
symptoms and exercise capacity in each subsequent model cycle, were
predicted by the model risk equations; based on baseline patient
characteristics, treatment effect applied in the first cycle and predicted
status at the end of the model cycle immediately preceding the current
cycle. At each cycle, SGRQ was then predicted based on the predicted
FEV1, exacerbation frequency, COPD symptoms and exercise capacity
status in that cycle. Outcomes were modeled for FF/UMEC/VI and
BUD/FOR separately.
As the model predicts changes in SGRQ total score based on changes
in FEV1 and exacerbation frequency, and changes in exacerbation fre-
quency based on changes in FEV1, adjustments were made to prevent
over or under prediction of outcomes compared with those observed.
This adjustment was achieved by first inputting the FEV1 treatment
effect from FULFIL and then adjusting exacerbation treatment effects
predicted by the model so that it was the same as that observed in
FULFIL. The same procedure was then applied sequentially with the
SGRQ treatment effect predicted by the model based on FEV1 and ex-
acerbation treatment effects. Predicted SGRQ for the first model cycle
was calibrated to align with the change from baseline score observed in
FULFIL, and the likelihood of measurement at 24 weeks coinciding with
an exacerbation was small. Therefore, the risk of double counting the
impact of exacerbations on QALYs, over the time horizon of this ana-
lysis, was very low.
2.2.3. Cost inputs
Costs were calculated using the resource-use risk equations in the
GALAXY-COPD model [16]. Unit costs were applied to predicted annual
counts of general ward days, intensive care unit (ICU) days, ER visits,
office visits, day/night home visits, and outpatient visits. Unit costs
(Table 2) were obtained from the 2016 Personal Social Services Re-
search Unit (PSSRU) or the 2015/2016 NHS National Schedule of Re-
ference costs [23,24]. Costs from 2015 were inflated to 2016 values
using the PSSRU Hospital & Community Health Services Index [23] and
subsequently inflated to 2017 values using the UK Consumer Price
Index [25].
A scenario based on indirect costs utilized productivity losses in-
curred by sick leave, estimated according to the human capital ap-
proach, or gross value lost during time absent from usual activities. As
data were not available from FULFIL, the Salford Lung Study (SLS) [26]
was used to estimate the duration (mean [standard error, SE]) of
moderate and severe exacerbations: 12.8 (0.38) days and 31.3 (0.71)
days, respectively (calculated average across both treatment arms). The
duration of exacerbations was assumed to be the same as the number of
days absent from usual activities.
Medication costs were obtained from the online Monthly Index of
Medical Specialities (2017) [27] and are shown in Table 3. Quantities
of rescue medication were based on use in patients in the FULFIL ITT
population (Table 1).
2.2.4. Utilities
A published algorithm was used to translate annual SGRQ total
scores to an annual utility value [28], as follows:
EQ-5D = 0.9617 – (0.0013*SGRQ total) – (0.0001*[SGRQ
total2]) + (0.0231*male).
2.2.5. Model assumptions
No waning of treatment effect was considered in the analysis.
Treatment discontinuation in the first year of therapy was assumed to
be 8% with FF/UMEC/VI and 13% with BUD/FOR, based on results in
the FULFIL ITT population at 24 weeks (no data on discontinuation at
Table 2
Unit costs for healthcare resource.
2017 costs Source DRG description/methods summary
Hospital costs
Cost per day in ICU £1,340 NHS SRC Adult critical care, 0–6 organs supported – code XC01Z-XC06Z
Cost per day in general ward £436 NHS SRC Weighted average costs by all COPD severities for non-elective long stay
ER visit £201 NHS SRC VB05Z, emergency medicine, category 2 investigation with category 3 treatment, type 1 non-admitted
Hospital outpatient visit – initial visit £196 NHS SRC CL, WF01B – respiratory medicine
Hospital outpatient visit – subsequent visit £149 NHS SRC CL, WF01A – respiratory medicine
Physician visit costs
Daytime home visit £133a PSSRU 2011 (Home visit lasting 23.4min)
Night time home visit £133 Assumption Assumed same as daytime home visit
Visit to physician's office £68a PSSRU 2015 (Clinical consultation lasting 17.2min)
Telephone consultation £28a PSSRU 2015 (Clinical consultation lasting 7.1min)
COPD=chronic obstructive pulmonary disease, DRG=diagnosis related group, ER= emergency room, ICU= intensive care unit, NHS = National Health Service,
PSSRU = Personal Social Services Research Unit, SRC= scheduled reference costs.
a Inflated to 2016 £ (by using PSSRU [23] Hospital & Community Health Services Index 2016); 2016 costs were then updated to 2017 values using the Consumer
Price Index data obtained from ONS [25].
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52 weeks were available; see also Supplementary Appendix).
Thereafter, treatment discontinuation was assumed to be 0% in all
subsequent years; it is reasonable to assume that after the first year,
patients are unlikely to discontinue, since COPD is chronic and treat-
ment usually additive. For cost of subsequent therapy (Table 3), all
patients discontinuing treatment were assumed to switch to other
classes of medication, in the same proportions as observed in FULFIL for
the combined treatment groups. Under these assumptions, subsequent
treatment was: ICS/LABA, 40%; ICS/LAMA/LABA, 36%; LAMA/LABA,
15%; and LAMA, 9%. Costs for each treatment class were based on the
treatment most frequently prescribed within each class in the UK
(Supplementary Table 2). The efficacy of all subsequent treatments was
assumed to be equivalent to BUD/FOR.
2.3. Model outputs
Model outputs included moderate and severe exacerbation rates,
LYs gained, QALYs gained, and an incremental cost-effectiveness ratio
(ICER), presented as incremental cost per QALY gained.
2.4. Scenario analyses
Scenario analyses examined the effect of alternative populations,
assumptions and model settings on the base-case results. These were as
follows: using patient baseline characteristics and results for the EXT
population from FULFIL (52-week follow-up; see Supplementary
Table 1), time horizon of five or 10 years, discount rate (both costs and
outcomes) of 0% and 5%, duration of treatment effect of three years,
alternative discontinuation rates (ongoing treatment discontinuation at
the same rate as the first year [FF/UMEC/VI, 8%; BUD/FOR, 13%] and
no discontinuation in the first and subsequent years), generic cost for
BUD/FOR, and inclusion of indirect costs (patient productivity).
2.5. One-way sensitivity analyses
Sensitivity analyses were conducted on baseline covariate values
that were not available from FULFIL data (baseline values for fi-
brinogen, 6MWT and mMRC dyspnea scores) and on treatment effects
(FEV1, SGRQ and exacerbations) (Supplementary Table 3). The varia-
tions explored were as follows: upper and lower bands of 95% con-
fidence intervals (CIs) around the base-case treatment effects on FEV1,
SGRQ, moderate exacerbation reduction, and severe exacerbation re-
duction. For the predicted values for parameters not obtainable from
FULFIL, fibrinogen and 6MWT values were varied to 95% CI limits
approximated using data from the ECLIPSE study, and±25% limits
were used for mMRC dyspnea score due to the analogous nature of the
data.
2.6. Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was conducted to address
the uncertainty in the parameters used within the model by assigning
distributions to input parameters (Supplementary Table 4) and ran-
domly sampling over 1,000 Monte Carlo simulations from these dis-
tributions (see also Supplementary Appendix). Normal/log-normal
distributions were used for treatment effects, and coefficients for the
risk equations were sampled using correlated draws from a Cholesky
decomposition table, developed from the covariance matrices for each
equation. The outputs of this analysis were summarized as 95% ranges,
scatter plots of incremental cost-effectiveness, and cost-effectiveness
acceptability curves (CEAC), for FF/UMEC/VI versus BUD/FOR. While
statistical distributions for the coefficients in the algorithm for mapping
SGRQ total score to EQ-5D were not available, the coefficients for the
risk equation predicting SGRQ were included in the PSA. Uncertainty
around HRQoL benefit was therefore tested in the following two ways:
1) directly by prediction of SGRQ and uncertainty in the specific risk
equation [16]; and 2) with the treatment effect and 95% CI around the
treatment effect on the clinical outcomes based upon which SGRQ was
predicted. Uncertainty in predicted QALYs was, therefore, explored.
3. Results
3.1. Base case
The predicted cumulative total number of moderate and severe
exacerbations per patient over a lifetime was lower with FF/UMEC/VI
compared with BUD/FOR (Table 4), with the FF/UMEC/VI group ex-
periencing 2.06 (95% CI: −3.76, −0.39) fewer moderate and severe
exacerbations versus the BUD/FOR group.
Total costs were greater with FF/UMEC/VI compared with BUD/
FOR (£20,842 versus £19,190), mainly as a result of higher drug costs.
The longer survival of patients in the FF/UMEC/VI group contributed to
the higher non-drug costs (£15,542 for FF/UMEC/VI versus £15,153 for
BUD/FOR). Overall, treatment with FF/UMEC/VI resulted in an addi-
tional 0.764 LYs (undiscounted) and 0.492 QALYs gained, at an addi-
tional mean cost per patient treated of £1,652 (95% CI: £723, £2,462)
compared with BUD/FOR, resulting in an ICER of £3,357 (95% CI:
£1,816, £5,194) per QALY gained.
Table 3
Drug unit costs.
Brand name Molecule Dose Pack size Pack cost Cost per dose Cost per day Label dosinga
Trelegy FF/UMEC/VI 100μg/62.5μg/25 μg 30 £49.50 £1.65 £1.65 1 inhalation per day
BUD/FOR
Symbicort, (Symb 400)b BUD/FOR 400μg/12 μg 60 £38.00 £0.63 £1.27 1 inhalation twice daily
DuoResp Spiromax (DuoR 320)c BUD/FOR 320μg/9 μg 60 £29.97 £0.50 £1.00 1 inhalation twice daily
Subsequent therapy medications
Tiotropium (Spiriva) TIO 18 μg 30 £34.87 £1.16 £1.16 1 inhalation per day
Seretide Accuhaler (SertA500) SAL/FP 500μg/50 μg 60 £40.92 £0.68 £1.36 1 inhalation twice daily
Ultibro Breezhaler IND/GLY 110μg/50 μg 30 £32.50 £1.08 £1.08 1 inhalation per day
Anoro ELLIPTA UMEC/VI 62.5μg/25 μg 30 £32.50 £1.08 £1.08 1 inhalation per day
Rescue medication
Ventolin Accuhaler SALB 200 μg 60 £3.60 £0.06 £0.06 1
According to Monthly Index of Medical Specialties 2017 [27].
BUD=budesonide, FOR= formoterol, FF=fluticasone furoate, FP=fluticasone propionate, GLY=glycopyrronium, IND= indacaterol, SAL= salmeterol,
SALB= salbutamol, TIO= tiotropium, UMEC=umeclidinium, VI= vilanterol.
a Label dosing was obtained from the Monthly Index of Medical Specialties 2017 [27].
b Used for costing of interventions in the model, unless other otherwise specified (i.e., in scenario analyses).
c This is equivalent to a metered dose of 400μg/12 μg for BUD/FOR (based on product monograph) used for scenario analyses where the generic price for BUD/
FOR was tested.
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3.2. Scenario and sensitivity analyses
In most of the scenarios analyzed, the ICER was between £2,000 and
£5,000 per QALY gained (Table 5); two scenarios were outside of this
range: (1) considering a three-year duration of treatment effect, and (2)
including patient productivity costs.
Alternative assumptions about discount rate, treatment discontinuation
rate, or time horizon resulted in relatively small changes to the ICER. The
ICER was lower (£2,262 per QALY gained) if baseline characteristics and
results for the FULFIL EXT population were used in place of those for the
ITT population analysis, and was greater (£4,718) if generic BUD/FOR cost
was substituted in. The scenario associated with the highest ICER (£9,902)
was limiting the duration of treatment effect to three years. In contrast, FF/
UMEC/VI was dominant over BUD/FOR (i.e., FF/UMEC/VI was less costly
and more effective) if patient productivity costs were included in the model.
As with the base-case lifetime horizon, the predicted lifetime cumulative
total number of moderate and severe exacerbations per patient was lower
with FF/UMEC/VI compared with BUD/FOR, for both five-year (3.6 versus
4.7, respectively) and 10-year (6.2 versus 8.1, respectively) time horizons
(Supplementary Fig. 1). Predicted survival rates were higher with FF/
UMEC/VI compared with BUD/FOR after five and 10 years (80.3% versus
77.5%, and 49.2% versus 43.3%, respectively; Supplementary Table 5).
Results of one-way sensitivity analyses are shown in Table 6.
The results were most sensitive to changes in SGRQ and severe ex-
acerbation treatment effects. Applying the upper and lower 95% confidence
limits for risk reduction of severe exacerbation gave the largest ICER range,
from £2,466 to £5,556. The PSA found that FF/UMEC/VI had a higher cost
and produced more QALYs than BUD/FOR in all simulations (Fig. 1A).
Overall, the results of the scenario and sensitivity analyses were all below
the cost-effectiveness threshold of £20,000 [29].
For 95% of the 1,000 simulations, the ICER lay between £1,816 and
£5,194; the probability of FF/UMEC/VI being cost-effective at a will-
ingness-to-pay threshold of £20,000 was 100% (Fig. 1B).
4. Discussion
In this study, we used the previously developed and validated GALAXY-
COPD linked-risk equation model to assess the cost-effectiveness of treating
moderate-to-severe COPD with once-daily FF/UMEC/VI versus twice-daily
BUD/FOR from a UK NHS perspective. FF/UMEC/VI was associated with
increases in LYs and QALYs, but also with higher costs, compared with
BUD/FOR. Non-drug costs were higher for patients receiving FF/UMEC/VI
compared with those receiving BUD/FOR, despite lower rates of moderate
and severe exacerbations. A major contributor to this was the longer sur-
vival in the cohort on FF/UMEC/VI, illustrated in a scenario analysis at a
shorter time horizon of five years, where non-drug costs were higher with
BUD/FOR (£7,761) compared with FF/UMEC/VI (£7,639). This suggests
that the higher acquisition cost of FF/UMEC/VI would be offset by health
service savings elsewhere, particularly as a result of the difference in the
per-patient yearly rate of severe exacerbations (requiring hospital admis-
sion), which was 42% lower in the FF/UMEC/VI group compared with the
BUD/FOR group (see Table 4). The ICER of £3,357 per QALY gained in the
base case and equivalent costs in the scenario and sensitivity analyses were
all within the willingness-to-pay threshold of £20,000 that is generally
considered to be a cost-effective use of healthcare resources in the UK [29];
thus, the health gain with FF/UMEC/VI versus BUD/FOR justifies the higher
treatment acquisition cost. The base-case study was conducted from a UK
NHS perspective, according to NICE guidelines [22], and did not include
estimates of effects on productivity.
One of the strengths of the GALAXY-COPD model is that it draws on a
wide range of patient characteristics and clinical measures to extrapolate to
longer-term outcomes from shorter-term data, in this case, the 24-week ITT
data from FULFIL. However, the need to make assumptions regarding the
duration of treatment effect and treatment discontinuation after one year
may be considered as limitations of the analysis. Results were sensitive to
the duration of treatment effect, with the ICER increasing to £9,902 if the
duration of treatment effect was limited to three years compared with the
base case, where treatment effect was assumed to continue for the time
Table 4
Accumulated outcomes (lifetime time horizon).
FF/UMEC/VI BUD/FOR
Cumulative number of exacerbations over timeframe (discounteda):
Moderate 6.629 7.664
Severe 1.764 2.792
Total 8.393 10.456
Severe exacerbations PPPY 0.174 0.299
Total exacerbations PPPY 0.830 1.119
Outcomes at end of timeframe
Accumulated LYs (undiscounted) 10.107 9.343
Accumulated QALYs (discounteda) 5.150 4.657
Costs at end of timeframe (discounteda)
Drug costs £5,300 £4,037
Total non-drug costs £15,542 £15,153
Hospital costs £14,316 £13,973
Outpatient/hospital/clinic costs £799 £766
Physician visits (office, home, day or night) £427 £414
Total accumulated costs £20,842 £19,190
Incremental results (mean, 95% CI)
Incremental cost £1,652 (£723, £2,462)
Incremental LYs 0.764 (0.33, 1.17)
Incremental QALYs 0.492 (0.29, 0.69)
ICER (per QALY gained) £3,357 (£1,816, £5,194)
BUD=budesonide, CI= confidence interval, FF=fluticasone furoate,
FOR= formoterol, ICER= incremental cost-effectiveness ratio, LY= life year,
PPPY=per patient per year, QALY=quality-adjusted life year,
UMEC=umeclidinium, VI= vilanterol.
a Discounts applied at 3.5%.
Table 5
Scenario analyses for FF/UMEC/VI versus BUD/FOR.
Scenario Incremental costs Incremental QALYs ICER (cost per QALY gained)
Base case £1,652 0.492 £3,357
EXT populationa £1,327 0.587 £2,262
Patient productivity costs –£2,177 0.492 Dominant
Discount rate 0% £2,299 0.666 £3,454
Discount rate 5% £1,455 0.438 £3,323
Duration of treatment effect: three years £862 0.087 £9,902
Treatment discontinuation excluded in first and subsequent years £1,841 0.525 £3,507
Treatment discontinuation included in first and subsequent years £986 0.347 £2,840
Generic price for Symbicort (DuoResp 320 [BUD/FOR]) £2,321 0.492 £4,718
Time horizon: five years £422 0.135 £3,134
Time horizon: 10 years £892 0.298 £2,992
BUD=budesonide, FOR= formoterol, ICER= incremental cost-effectiveness ratio, QALY=quality-adjusted life year.
a EXT=52-week extension population of the FULFIL trial [11].
M. Schroeder, et al. Respiratory Medicine: X 1 (2019) 100008
6
patients remained on treatment. However, a longer efficacy duration is a
reasonable assumption, based on the findings of the Understanding
Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial
that reported four-year sustained efficacy with a LAMA [30]. In addition,
the scenario using 52-week results from the FULFIL EXT population showed
a 33% reduction in the ICER compared with the base case. This reflects the
greater relative benefit, particularly on exacerbation reduction and im-
provement in SGRQ, seen with FF/UMEC/VI in the EXT population at 52
weeks, compared with at 24 weeks in the ITT population. Thus, the findings
of other studies and the analysis in the EXT population also increase con-
fidence in the results of the base-case analysis based on ITT data. While the
assumption that no treatment discontinuation would occur after one year
was based on limited evidence from longer studies [17,18], it was also seen
as reasonable from a clinical perspective since discontinuation due to lack of
efficacy or due to treatment-related adverse events is most likely to occur in
the first year; in scenario analyses, the assumption of ongoing treatment
discontinuation for all years did not greatly affect the ICER.
Other limitations of the study were, first, that the evaluation of cost-
effectiveness was based solely on clinical efficacy observed in the FULFIL
study. A comparison of FF/UMEC/VI with ICS/LABA combinations other
than BUD/FOR could potentially provide differing levels of cost-effective-
ness, although the recent Informing the Pathway of COPD Treatment
(IMPACT) trial, which favorably compared FF/UMEC/VI with FF/VI [31],
further substantiates the benefit of ICS/LAMA/LABA versus ICS/LABA.
Second, was the need to estimate required parameters for the GALAXY-
COPD model as they were unavailable from the FULFIL data. Although
responses to the EXACT-PRO were a suitable substitute for mMRC dyspnea
score, the 6MWT and plasma fibrinogen were predicted based on values
from the published ECLIPSE study [17]. While the use of predicted values
based on a single study might not be considered ideal, varying the baseline
parameters for the 6MWT or fibrinogen in the one-way sensitivity analyses
in the current study had only limited effects on the ICER for FF/UMEC/VI
treatment compared with BUD/FOR. With this in mind, future clinical trials
may consider including the 6MWT as an outcome and fibrinogen as a
baseline characteristic, due to their prognostic value for the modelling of
long-term treatment effects. Third, the effectiveness of subsequent therapy
was not known and was assumed in this analysis to be similar to the re-
ference treatment. However, triple therapy may have been more effective
than the reference treatment, and it is possible that this assumption de-
creased the total benefit to a greater extent in the BUD/FOR arm (which had
the higher discontinuation rate) than the FF/UMEC/VI arm. Thus, assuming
the effectiveness of subsequent therapy to have been closer to triple therapy
could have reduced incremental QALYs and increased the ICER. None-
theless, given that discontinuation was only applied in the first year, the
effect of this assumption was likely to have been small. Fourth, the popu-
lation of TORCH, from which the risk equations for HRU were developed,
was not specifically a UK population. Similar to other large COPD studies
suitable for disease modelling, TORCH was multi-national; however, with
50% of patients from Europe and 31% of patients from Western Europe
[18], the HRU rates in TORCH were likely similar to those of the UK.
Furthermore, the coefficients of the HRU risk equations were included in
the PSA. Finally, FULFIL only included patients who were considered GOLD
group D at enrollment (FEV1<50% predicted and CAT score≥10; or FEV1
≥50–<80% predicted, CAT ≥10 and either ≥2 moderate exacerbations
or ≥1 severe exacerbation in the previous 12 months) [11], limiting the
population included in the study. Accordingly, the results of this economic
evaluation are only generalizable to this limited patient population.
5. Conclusions
In conclusion, treatment with FF/UMEC/VI compared with BUD/FOR
Table 6
One-way sensitivity analyses for FF/UMEC/VI versus BUD/FOR.
Upper confidence limit Lower confidence limit
Incremental
costs
Incremental
QALYs
ICER (cost per QALY gained) Incremental costs Incremental QALYs ICER (cost per QALY gained)
Base case £1,652 0.492 £3,357 – – –
Fibrinogen (465.9–475.2 μg/dL) £1,638 0.490 £3,346 £1,659 0.493 £3,362
6MWT (365.3–376.1m) £1,731 0.519 £3,334 £1,717 0.515 £3,337
mMRC dyspnea score ≥2 (32–53%) £1,621 0.488 £3,324 £1,677 0.495 £3,386
Incremental FEV1 (148–194mL) £1,806 0.521 £3,468 £1,492 0.462 £3,227
RR for moderate exacerbation (0.6–1.04) £1,399 0.461 £3,034 £1,841 0.515 £3,578
RR for severe exacerbation (0.27–1.08) £2,422 0.436 £5,556 £1,282 0.520 £2,466
SGRQ change (−3.5 to −1) £1,652 0.370 £4,466 £1,652 0.622 £2,656
6MWT=6-minute walk test, FEV1= forced expiratory volume in 1 s, ICER= incremental cost-effectiveness ratio, mMRC=modified Medical Research Council,
QALY=quality-adjusted life year, RR= relative risk, SGRQ = St. George's Respiratory Questionnaire.
Fig. 1. Probabilistic sensitivity analysis results for FF/UMEC/VI versus
BUD/FOR showing a) base case, incremental cost-effectiveness plane and
b) cost-effectiveness acceptability curve.
BUD=budesonide, FF=fluticasone furoate, FOR= formoterol,
QALY=quality-adjusted life year, UMEC=umeclidinium, VI= vilanterol.
M. Schroeder, et al. Respiratory Medicine: X 1 (2019) 100008
7
resulted in a reduction in the total cumulative number of exacerbations,
including severe events. This economic analysis found FF/UMEC/VI to be
cost-effective for the UK NHS, compared with BUD/FOR, in patients with
COPD who are symptomatic and at risk of an exacerbation. Sensitivity
analyses showed that variation in key input parameters did not alter the
results. These results may be useful for informing drug listing decision-
making processes in the UK healthcare system.
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